Clinical Trial

ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main objective of this study is to compare the efficacy of HS-20093 with standard of care (SOC) on prolonging overall survival (OS) in subjects with relapsed small cell lung cancer (SCLC).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-07-06; most recent amendment 2024-10-15.
Status change: Not Yet Recruiting → Recruiting 2024-10-11
Trial Details
NCT Number NCT06498479
Lead Sponsor Hansoh BioMedical R&D Company
Conditions Small Cell Lung Cancer
Enrollment 460 participants
Start Date 2024-07-04
Primary Completion 2026-09-30 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2024-10-16